Pre-made Tiragolumab benchmark antibody ( Whole mAb, anti-TIGIT therapeutic antibody, Anti-VSIG9/VSTM3/WUCAM Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tiragolumab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tiragolumab is another precision cancer immunotherapy human monoclonal antibody that targets TIGIT, an inhibitory immune checkpoint that like PD-L1 is expressed on tumor-infiltrating immune cells like T cells and NK cells.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-579-1mg	1mg	3090
GMP-Bios-ab-579-10mg	10mg	Inquiry
GMP-Bios-ab-579-100mg	100mg	Inquiry
GMP-Bios-ab-579-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tiragolumab biosimilar, Whole mAb, Anti-TIGIT Antibody: Anti-VSIG9/VSTM3/WUCAM therapeutic antibody
INN Name	Tiragolumab
Target	TIGIT
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Genentech
Conditions Approved	na
Conditions Active	Non-small cell lung cancer;Solid tumours;Oesophageal cancer;Small cell lung cancer;Squamous cell cancer;Cervical cancer;Liver cancer;B-cell lymphoma;Breast cancer;Multiple myeloma
Conditions Discontinued	na
Development Tech	na